News

Dr Moreno has held research positions at Merck, Amgen, Corvas International, and Dendreon where he served as senior director of chemistry. Dr Moreno has received his doctorate in

Investors included HealthCare Ventures, Fidelity Biosciences, New Enterprise Associates, Novartis Option Fund and Genzyme Ventures. Christopher Mirabelli, chairman of the board of Proteostasis, said: “The significant series A

Under the terms of the agreement, Baxter will pay a license fee and will make contingent clinical, regulatory and commercial milestone payments. Baxter will also contribute to the

The collaboration seeks to develop new, improved treatments for specific patient groups most at risk for malaria, an often fatal infectious disease of developing countries, particularly affecting pregnant

Dong-A PharmTech’s marketing partner, Valenta Pharmaceuticals, is set to launch Zydena during the fourth quarter of 2008. According to the company, Zydena (generic name, udenafil) is a new

The company believes that it is the first to file an abbreviated new drug application containing a paragraph IV certification for FazaClo. Cima Labs and Azur Pharma and

Acording to the company, RVX-208 is the only novel small molecule that is specifically designed to increase ApoA-I production and thereby raise high-density lipoprotein levels thus enhancing HDL

With this agreement, Spacelabs now employs Oridion Microstream capnography technology in its new, compact and ultra-lightweight patient monitoring system, elance. Microstream capnography technology and FilterLine breath sampling products

The agreement provides North Med with the rights to sell in the Czech Republic and the Slovak Republic, and includes minimum purchase requirements. The SonaStar is used by